Efficacy and safety of platelet inhibitors.

Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. Ther Clin Risk Manag (2015) 0.80

The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health (2009) 2.39

Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res (2011) 1.37

Adverse drug reactions induced by valproic acid. Clin Biochem (2013) 1.14

From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system. Pharmacogenomics (2010) 1.01

Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. AIDS Res Treat (2012) 0.94

HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. Int J Hepatol (2012) 0.93

The Link between Hypersensitivity Syndrome Reaction Development and Human Herpes Virus-6 Reactivation. Int J Hepatol (2012) 0.91

Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci (2014) 0.90

Hyaluronic acid and wound healing. J Pharm Pharm Sci (2015) 0.89

Single-nucleotide polymorphisms in inflammatory bowel disease. Transl Res (2011) 0.88

Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf (2006) 0.88

Nutritional and probiotic supplementation in colitis models. Dig Dis Sci (2012) 0.87

Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res (2009) 0.86

In vitro anti-inflammatory effects of hyaluronic acid in ethanol-induced damage in skin cells. J Pharm Pharm Sci (2011) 0.84

Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol (2014) 0.84

Metabolome and inflammasome in inflammatory bowel disease. Transl Res (2011) 0.83

Ibuprofen-induced hypersensitivity syndrome. Transl Res (2010) 0.83

Changes in the pathogenesis of alcohol-induced liver disease -- preclinical studies. Exp Mol Pathol (2013) 0.83

Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res (2012) 0.82

Hepatotoxicity of Pyrrolizidine Alkaloids. J Pharm Pharm Sci (2015) 0.81

Colorectal polyposis and immune-based therapies. Can J Gastroenterol (2004) 0.80

Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic. J Gastrointestin Liver Dis (2008) 0.79

Risk of infections of biological therapies with accent on inflammatory bowel disease. J Pharm Pharm Sci (2014) 0.78

Colon polyps and cytokines: emerging immunological mechanisms. Rom J Gastroenterol (2003) 0.77

Apoptosis in liver disease. Rom J Gastroenterol (2002) 0.77

Drug-induced severe adverse reaction enhanced by human herpes virus-6 reactivation. Transl Res (2013) 0.77

Non-Alcoholic Steatohepatitis: Clinical and Translational Research. J Pharm Pharm Sci (2016) 0.76

Nonmedicinal interventions in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol (2015) 0.75

Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery. Dig Dis Sci (2012) 0.75

Mechanism of Impila (Callilepis laureola)-induced cytotoxicity in Hep G2 cells. Clin Biochem (2002) 0.75

Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf (2003) 0.75

Valproic acid derivatives signal for apoptosis and repair in vitro. Clin Biochem (2013) 0.75

Tumor necrosis factor alpha as a noninvasive marker of liver inflammation in patients with viral hepatitis C. Am Clin Lab (2002) 0.75